May 17, 2022 | Bryan Johnson
Kernel x AppliedVR to Measure Treatment of Chronic Pain
Today, Kernel announced our partnership with AppliedVR, a pioneer in immersive digital therapeutics, adding to our existing partnerships with industry pioneers such as Cybin (watch) & Aim Lab (watch).
We are launching a joint study evaluating the effects of AppliedVR’s FDA-authorized VR-based program on the brains of 20 patients with chronic lower-back pain. In the U.S., approximately 12% of all adults experience chronic lower-back pain. A 2020 study in the Journal of American Medical Association found that costs associated with lower-back and neck injury topped $134B, making it the highest-cost category of health spending in the country.
Our partnership with AppliedVR is an exciting opportunity to illuminate and unlock insight on specific biomarkers related to chronic pain, one of the most debilitating and costly medical conditions in our healthcare system. These biomarker-based insights may someday be used to evaluate the effectiveness of treatments and personalize them to individuals.
The goal is to evaluate quantifiable differences in measured brain activity for the treatment and control groups, and collect biodata to better understand how VR engages the brain. Kernel Flow’s ability to measure brain-activity changes before, during, and after VR use will enable high-quality objective data.
“AppliedVR is committed to being the most evidence-based immersive therapeutics provider in the world, which means we are constantly looking for smarter, more in-depth ways to not only demonstrate that the RelieVRx system delivers durable pain relief, but also to understand how it works on the brain,” said Josh Sackman, cofounder and president of AppliedVR.
Kernel Flow allows for a safe, natural, and comfortable brain-imaging experience. With Flow we are now able to examine the effect of any intervention on the brain, unlocking opportunities for businesses and individuals alike.